Sentences with phrase «of docetaxel»

The hazard ratio for progression - free survival was 0.69 in favor of docetaxel (95 % CI, 0.52 — 0.93; P =.014).

There was one treatment - related death in the erlotinib group, and 22.1 % of docetaxel patients and 29.0 % of erlotinib patients suffered adverse events that led to dose modification.

A total of 27 % of docetaxel patients had grade 3 or 4 neutropenia, and 29 % had alopecia of any grade; 14 % of erlotinib patients suffered grade 3 or 4 dermatological toxicities.

Almost 72 % of docetaxel patients were current or former smokers, compared with 81.7 % in the erlotinib group.

CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

Patients received 3 cycles of docetaxel at either 80 mg / m2 or 100 mg / m2 and trastuzumab three times a week followed by 3 cycles of chemotherapy.

According to Joensuu, this suggested that the dose of docetaxel administered with trastuzumab may influence survival outcomes.

The addition of docetaxel not only lengthened survival but delayed disease progression as measured by an increase in prostate - specific antigen (PSA), the appearance of new metastases, or worsening symptoms.

Not exact matches

Previous results from the trial have already changed clinical practice — data released last year has led to docetaxel chemotherapy now being part of the standard of care for many men with prostate cancer.

Sengupta and his colleagues took breast cancer cells that did not have the markings of CSCs and exposed them to docetaxel, a common chemotherapy drug.

Median overall survival of patients receiving nivolumab was 9.2 months, compared with six months for patients who received docetaxel.

Findings were presented at the WCLC are based on the updated results of 12 lung cancer patients enrolled in the clinical trial with pembro and irinotecan or gemcitabine with or without vinorelbine or docetaxel.

The team gave 137 women with breast cancer either T - DM1 or the standard treatment of Herceptin plus another drug, docetaxel.

Maintenance chemotherapy was left to the discretion of the treating medical oncologists and consisted of pemetrexed, docetaxel, erlotinib or gemcitabine.

The tissues were grown on a 3D gelatin sponge, and two portions of the same tumor were treated with either cabazitaxel or docetaxel.

If prolongation of life was the primary therapeutic objective and the patients were eligible for docetaxel treatment, the G - BA specified docetaxel in combination with prednisone or prednisolone as appropriate comparator therapy (docetaxel population).

Analysis of the tumor genes affected by the two drugs revealed that cabazitaxel had a greater effect on cellular division and regulation of chromatin — a spool for DNA that helps control which genes are in use and when — whereas docetaxel has a greater impact on DNA transcription and repair.

This was offset by a hint of considerably greater harm from radium - 223 + BSC due to more frequent, but never severe, diarrhea in patients without docetaxel pretreatment.

It was assumed in the assessment that most of the remaining patients actively decided against docetaxel treatment.

The researchers showed that cabazitaxel worked better than docetaxel in human prostate cancer cells lines that were resistant hormone treatment, both in terms of slowing cancer - cell growth and in its ability to kill cancer cells.

The majority of patients included in the study were not eligible for docetaxel because their disease had progressed despite pretreatment with this drug (approximately 57 %).

If docetaxel treatment was not an option for the patients or if the primary treatment goal was the relief of symptoms, the so - called «symptom control,» and the prevention of complications, the G - BA specified BSC as appropriate comparator therapy (BSC population).

No evaluable data were available for the comparison with docetaxel in patients in whom prolongation of life was the primary treatment goal.

Researchers from BIND Biosciences in Boston filled nanoparticles with the cancer drug docetaxel and injected them into the blood of 17 people who had cancers that are normally resistant to the drug.

This nanoparticle — one - thousandth the width of a human hair — carries a load of a lethal chemical: docetaxel, which is currently used to treat prostate cancer.

One such compound was docetaxel, an anticancer drug that binds tubulin, and the other jasplakinolide, which specifically binds the cytoskeletal form of actin.

Results also showed 27.7 percent of patients in the ADT plus docetaxel arm had a decline in prostate specific antigen (PSA) to less than 0.2 ng / mL at 12 months compared with 16.8 percent for those taking ADT alone.

Research coordinated by the ECOG - ACRIN Cancer Research Group, supported in part by the National Cancer Institute, and published in the current online version of The New England Journal of Medicine, examined the outcomes of giving the chemotherapy drug docetaxel at the start of ADT.

Results showed an increased survival of 13.6 months for patients treated with ADT plus docetaxel than with ADT alone.

It included 790 patients (median age of 63 years) who were enrolled and randomized from July 2006 to November 2012 to receive either ADT plus docetaxel every three weeks for six cycles or ADT alone.

The men receiving docetaxel had an average of 32.7 months before the cancer progressed by worsening scan results or symptoms, compared to 19.8 months for hormone therapy alone.

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 months.

Long - term follow - up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.

CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model.

«Biomarkers determining who will or will not completely respond to neoadjuvant TCHP [trastuzumab, carboplatin, docetaxel, and pertuzumab] are lacking,» wrote study authors led by Jeremy Force, DO, of Duke University School of Medicine in Durham, North Carolina.

Comparative benefits of Nab - paclitaxel over gemcitabine or polysorbate - based docetaxel in experimental pancreatic cancer.

In contrast, among those who received 80 mg / m2 docetaxel, 12 months of trastuzumab had superior disease - free survival.

RNA - sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel.

The main purpose of this study is to find out more about the side effects of the study drug, MM - 121, when combined with the study drugs, docetaxel or pemetrexed, and to learn if cancer cell growth (disease progression) is delayed in people taking MM - 121 with docetaxel or pemetrexed.

Researchers are also trying to learn about: - The level of MM - 121 that remains in the human body at different time points when MM - 121 is combined with docetaxel or pemetrexed - The relationship between the biomarker, heregulin, and cancer cell growth (disease progression) in people dosed only with docetaxel or pemetrexed.

However, subset analyses of phase III trials suggest that patients with EGFR mutation - positive NSCLCs do not benefit from immunotherapy compared with docetaxel.

Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triplenegative breast cancers.

The median age of patients was similar between the two groups, at 67 in the docetaxel group and 66 in the erlotinib group.

Inclusion Criteria: • The participant may have no more than 2 prior lines of systemic therapies (neoadjuvant and adjuvant therapies will not be considered as a prior line of therapy) for advanced or metastatic disease and is suitable to receive gemcitabine and docetaxel therapy.

The U.S. drug maker released a statement on Monday saying that its Keynote - 010 study, a randomized Phase two - third trial, showed that patients who were taking two different doses of Keytruda (FDA - approved two mg / kg dose and treatment dose of 10 mg / kg given every three weeks) had longer survival compared to those who took docetaxel, the drug widely used for non-small cell lung cancer (NSCLC).

A total of 28.9 % of patients receiving docetaxel had not progressed after 6 months, compared with 16.9 % of erlotinib patients.

Pertuzumab was approved by the FDA in 2012 for first - line treatment of HER2 + metastatic breast cancer in combination with trastuzumab and the chemotherapy docetaxel (Taxotere).

In 2014, researchers at the National Cancer Conference made the following statement: «Long term significant scalp alopecia (here lasting for up to 3.5 years following completion of chemotherapy) may affect 10 - 15 % of patients following docetaxel for EBC [early breast cancer].